Fatalities following allergen immunotherapy
Allergen immunotherapy has been in use for nearly 100 yr and has become an important method of reducing allergic symptoms in select patients with allergic rhinitis, asthma, and insect venom hypersensitivity. Unfortunately, immunotherapy has been associated with anaphylaxis and death. Although the relative risk of severe reactions to immunotherapy is low, the number of such reactions has increased since the introduction of standardized and more potent extracts. There are a number of risk factors associated with such severe anaphylactic reactions. Such risk factors include errors in dosage, failure to reduce the dosage after a longer than scheduled interval, administration of the wrong extract, inadvertent intravenous administration, failure to postpone injection because of infection or asthma exacerbation, failure to observe patients for appropriate length of time, failure to adhere to guidelines for established contraindications, concurrent use of β-adrenergic blocking agents, uses of mixtures of allergens, immunotherapy during the active allergy season, and types of allergens. In this review, we focus on these and other risk factors in attempts to reduce the risk of anaphylaxis following allergen immunotherapy.
Index EntriesAllergen immunotherapy immunotherapy fatalities systemic reactions to immunotherapy anaphylaxis asthma rhinitis insect sting hypersensitivity
Unable to display preview. Download preview PDF.
- 1.Lamson, R. W. (1924), JAMA 82, 1090–1098.Google Scholar
- 2.Lamson, R. W. (1929) JAMA 93, 1775–1778.Google Scholar
- 7.Kordash, T., and Miller, J. (1997), J. Allergy Clin. Immunol. 99, S67.Google Scholar
- 8.American College of Allergy Asthma and Immunology. Fact Sheet: Efficacy and Safety of Immunotherapy. http://allergy.mcg.edu/patients/ factsheet.html.Google Scholar
- 11.Lüderitz-Püchel, U., May, S., and Haustein, D. (1996), Munch. Med. Wochenschr. 138, 129–132.Google Scholar
- 21.Malling, H.-J., and Weeke, B., eds. (1993), Allergy 48(14 Suppl), 7–35.Google Scholar
- 22.Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy. (1997), Med. J. Aust. 167, 540–544.Google Scholar
- 28.Müller, U., and Mosbech, H. (1993), Allergy 48(14 Suppl), 36–46.Google Scholar
- 29.Bousquet, J., Lockey, R. F., and Malling, H.-J. (1998), Allergy 53(Suppl 44), 1–42.Google Scholar
- 35.Practice parameters for allergen immunotherapy. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. (1996), J. Allergy Clin. Immunol. 98, 1001–1011.Google Scholar
- 41.Abramson, M. J., Puy, R. M., and Weiner, J. M. (2003), Cochrane Database Syst. Rev. 2, 2004.Google Scholar
- 42.Wilson, D. R., Torres Lima, M., and Durham, S. R. (2003), Cochrane Database Syst. Rev. 2, 2004.Google Scholar